India Globalization Capital

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma's strategic focus and vision for the future.

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quarter 2023 financial results.

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia Grimaldi, PFO, will be featured in an investor webinar hosted by Radius Research on Friday, Feb. 10, at 12:30 p.m. ET. They will discuss the Company's Phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer's and will participate in a question and answer session.

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

DALLAS--( BUSINESS WIRE )--Over the past year the influencer marketing industry remained resilient and continued to grow in its role and impact for marketers, reaching an estimated value of $16.4 billion1. And, in 2023, the creator marketing industry shows no signs of slowing down. LTK, the creator-guided shopping platform and global creator marketing platform, today released its State of Creator Guided Shopping Trends Report to help brands as they look to harness the power of creators to grow their business.

LTK Releases 2023 State of Creator Guided Shopping Trends Report

POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection letter from Health Canada for approval of its trial, “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease.” The no objection letter provides the acknowledgement of IGC-AD1's drug candidacy and the authority to proceed with Phase 2 trials in Canada.

IGC Receives No Objection Letter from Health Canada

POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at https://www.sec.gov/.

IGC Announces Updated Life Sciences Presentation

POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was signed into law by President Biden on Friday Dec. 2, 2022. The law provides legislation establishing a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development.

IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act

POTOMAC, Md.--( BUSINESS WIRE )--India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease”.

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer's Disease

POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am ET and will be available for one-on-one meetings on Monday, December 5 and Tuesday, December 6.

IGC to Present at the RHK 2022 Disruptive Growth Conference

IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Announces Issuance of Second Patent for the Treatment of Alzheimer's Using THC.

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer's Using THC

Applied Optoelectronics

Bright Minds Biosciences

Alaunos Therapeutics

Penny stocks to buy? High volume has placed them on the watch list in the stock market today.

4 High Volume Penny Stocks To Watch While The Stock Market Is Down

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces that at its ASM on Sep 9'22 all proposals as disclosed on the DEF 14A were passed by the requisite stockholders vote.

IGC Announces Results of its 2022 Annual Stockholders Meeting

Agrify

Akanda Corp

Cronos Group

Greenlane Holdings

Akerna Corp

Leafly Holdings

WM Technology

Chicago Atlantic Real Estate Finance

Village Farms International

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

Weed Stocks This Week: Major Earnings Blitz

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company's 2023 fiscal year.

IGC Reports Financial Results for the Quarter Ended June 30, 2022

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Reports Financial Results for Fiscal Year Ended March 31, 2022.

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022

BETHESDA, Md.--(BUSINESS WIRE)-- #IGC--IGC is excited to announce that one of its subsidiaries reached an IP license agreement for a potential Alzheimer's drug development candidate.

IGC Acquires Exclusive Rights for a Potential Alzheimer's Drug Development Candidate

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a patent (#11,351,152) to the Company titled “Method and Composition for Treating Seizure Disorders.” The patent is assigned to IGC and relates to compositions and methods for treating multiple types of seizure disorders and epilepsy in humans and animals, using a combination of the cannabinoid cannabidiol (CBD)

IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits.

India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC's Board appointed Ms. Claudia Grimaldi as a non-independent Director on Mar 23'22. IGC has 5 directors including a majority who are independent

India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors

India Globalization Capital, Inc. IGC announced its financial results for the three months ending December 31, 2021 – quarter three of the company's 2022 fiscal year. Q3 Financial Highlights

India Globalization Capital Posts Net Loss Of $2.38M For The Third Quarter

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces its financial results for the three months ending December 31, 2021 – quarter three of the Company's 2022 fiscal year.

IGC Reports Financial Results for the December 31, 2021 Quarter

GREENBELT, Md., Jan. 31, 2022 /PRNewswire/ -- The Rosen Law Firm, P.A.

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock - IGC

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Appoints Former Congressman Jim Moran to its Board of Directors.

India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug

News for India Globalization Capital Stock (IGC)